Panitumumab

Brand Name: Vectibix

Manufacturer: Amgen

Indication

Indication:

Metastatic colorectal cancer (mCRC) patients with left-sided primary tumours that express wild-type RAS (In combination with chemotherapy)

First-Line Treatment: In combination with chemotherapy (e.g., FOLFOX) for newly diagnosed metastatic colorectal cancer that is RAS wild-type, particularly for left-sided tumors.
Later-Line Treatment (Monotherapy): For patients whose cancer has progressed after receiving fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, provided it’s RAS wild-type.

Note: in PEI, panitumumab is reimbursed in the third-line setting. It has not yet been listed for reimbursement in the first-line setting.

Specific CRC Subtype: RAS wild-type

Stage: IV

Therapy Line: First-line, Third-line or later

Health Canada Approval: Approved

pCPA Negotiation Status: Completed

Reimbursed in: AB (Alberta), BC (British Columbia), MB (Manitoba), NB (New Brunswick), NL (Newfoundland and Labrador), NS (Nova Scotia), NU (Nunavut), NWT (Northwest Territories), ON (Ontario), QC (Quebec), SK (Saskatchewan), YU (Yukon)

New Search

Indication

LEARNING

GET INVOLVED

ABOUT US

CONNECT US